Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as TEV-56286 Test, Emrusolmin
TEV-56286 · 2 trials · 1 indication
The UMSARS is a multidimensional, validated scale for semi-quantitative clinical assessments of MSA participants. Modified UMSARS part I includes all items with the exclusion of item 11. Item scoring is scaled 0-3 using a range of 0 (no impairment) to 3 (severe impairment).
The UMSARS is comprised of 4 parts: part I, historical review of disease-related impairments, 12 items and part II, motor examination, 14 items. As UMSARS is a unified scale, each item in parts I and II achieves a single score using a range of 0 (no impairment) to 4 (severe impairment).
| Arm | Type | Description |
|---|---|---|
| TEV-56286 | EXPERIMENTAL | Orally administered capsules once daily |
| Placebo | PLACEBO_COMPARATOR | Orally administered capsules once daily |
| Name | Type | Description |
|---|---|---|
| TEV-56286 | DRUG | TEV-56286 capsules administered orally |
| Placebo | DRUG | Matching placebo administered orally |
Inclusion Criteria: * is considered to be "clinically possible" or "clinically probable" MSA as determined by the Gilman criteria * is medically and psychiatrically stable, as indicated by medical and psychiatric history, as well as physical and neurological examination * Females of child bearing p...
TEV-56286 is an investigational small molecule being studied for the treatment of Multiple System Atrophy, a rare neurological disorder. It is in Phase 2 clinical development and is not yet approved for any indication. Teva Pharmaceutical Industries Limited is developing the drug.
TEV-56286 is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. Teva is the sponsor of the clinical program evaluating the drug in Multiple System Atrophy.
TEV-56286 is in Phase 2 clinical development for Multiple System Atrophy. Both of its trials are Phase 2 studies and both are currently recruiting participants. The drug is investigational and has not been approved by the FDA or any other regulatory agency.
TEV-56286 is being evaluated in two Phase 2 trials: NCT06568237, which has an enrollment of 350 participants, and NCT07197866, an extension trial with an enrollment of 200 participants. Both are recruiting and are being conducted in the United States, France, Germany, Israel, Italy, Japan, and Spain.
Yes. TEV-56286 Test and TEV-56286 Dose A are alternative names used for TEV-56286, the same investigational small molecule developed by Teva Pharmaceutical Industries Limited for Multiple System Atrophy. Searches using any of these names refer to the same Phase 2 drug candidate.
Both Phase 2 trials of TEV-56286 in Multiple System Atrophy are randomized, double-blind, and placebo-controlled. Together they plan to enroll 550 participants aged 30 years and older, across seven countries. The trials do not use biomarker selection, and healthy volunteers are not eligible to participate.